This GIP-mediated enhancement of central GLP-1 delivery is a unique feature not available to mono-agonists, ensuring a more potent engagement of central pathways
It models your real-time drug concentration using published PK parameters from Coskun et al
The genetic test reveals predispositions in peptide-related pathways, not exact medication response
Bulk purchases often provide cost savings per unit while ensuring consistent supply
ABBREVIATIONS AND ACRONYMS CKD chronic kidney disease CVD cardiovascular disease CVOT cardiovascular outcome trials DPP4i dipeptidyl peptidase 4 inhibitors GLP1RA glucagon-like peptide 1 receptor antagonist HbA1c hemoglobin A1c HF heart failure MI myocardial infarction SGLT2i sodium glucose transporter 2 inhibitor T2DM type 2 diabetes mellitus TZD thiazolidinediones REFERENCES 1.Di Angelantonio E, Kaptoge S, Wormser D, et al
But with the introduction of Mounjaro, the number of written prescriptions increased dramatically (8% from July 2022 on), and eventually the number of adjudicated GLP-1 prescriptions doubled across all payer channels